Andrea Lobo

At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.

Articles by Andrea Lobo

News

$10M financing to advance Sharp’s oral Gaucher disease treatment

Sharp Therapeutics said it’s arranging a $10 million private investment to advance the development of ‘901, an oral treatment…

News

Monitoring lyso-Gb1 may aid choice to begin ERT in Gaucher disease

Measuring levels of glucosylsphingosine (lyso-Gb1), a diagnostic biomarker of Gaucher disease, in children confirmed by newborn screening programs to…